ZEISS and EDGE leverage AI to transform bioimaging in the biopharma industry

• Integrated solutions: Seamless integration of EDGE-developed quantitative assays with scalable hardware and AI-driven analytics from ZEISS to redefine bioimaging in biopharma
• Strategic focus: Enabling automation and enhancing decision-making through quantitative imaging, establishing an AI-native data foundation accelerating GenAI adoption
• Customer impact: Standardized high-throughput screening workflows reducing reliance on animal testing and delivering decision-grade insights through quantitative, AI-accelerated data analysis to drive innovation in the biopharma R&D

Through their collaboration, ZEISS and EDGE Biotechnologies aim to pioneer advanced biopharma solutions and reshape the role of bioimaging from a “niche tool” to a “core quantitative decision-making engine” in the biopharma industry.

By combining the leadership of ZEISS in optical innovation with EDGE’s assays and AI analytics, the collaboration aspires to deliver end-to-end solutions to customers that simplify their workflows, enhance their research capabilities, and enable faster decisions – as well as complementing customers’ existing AI missions with novel data sets.

The collaboration aims to leverage the combined strength of the two companies to deliver an integrated solution that positions bioimaging as a strategic enabler in the industry. At the core of the collaboration is a shared focus on quantitative bioimaging. It offers customers the possibility to move beyond images to standardized, assay-driven insights. Using EDGE-developed assays and AI-driven analytics, high-quality microscopy data is transformed into quantitative descriptions that inform R&D decisions, reducing uncertainty and timelines.

Biopharma is investing heavily in AI and digital infrastructure to accelerate the path from research to patients, enable more personalized medicine, and reduce reliance on animal testing. Yet the value of these ambitions is constrained by the biological data available. Much of today’s R&D still relies on endpoint assays and averaged readouts, which often cannot explain complex mechanisms such as delivery and efficacy. This creates a gap between the industry’s strategic goals and the need for scalable, high-quality single-cell and single-molecule data that capture these mechanisms. At the same time, teams need better decision support now – assays that reduce uncertainty, explain differences between candidates or formulations, and strengthen prioritization and go/no-go decisions within current workflows.

EDGE and ZEISS see a shared opportunity in generating high-content, time-resolved biological data linked directly to real biopharma questions. This includes establishing capabilities at biopharma sites, training personnel, and contributing to interpretation and decision-making. The assays both strengthen mechanistic understanding and provide data ready for GenAI, supporting better prediction and translation as well as increasing the long-term value of AI investments. In this way, better data can help biopharma move closer to its broader ambition: bringing more effective and personalized therapies to patients faster, with less trial-and-error and reduced dependence on animal testing.

By aligning their expertise, ZEISS and EDGE Biotechnologies aim to provide a unified value proposition that addresses the evolving operational and strategic needs of the biopharma industry.

This collaboration brings together advanced imaging systems (tailored to high-content, 3D, cellular analysis), seamless software integration embedding EDGE’s AI-driven analytics into ZEISS software environments, immersive user experiences through intuitive tools and interfaces that empower users to achieve deeper insights, end-to-end workflows tailored for biopharma from sample preparation to quantitative reporting, and onsite expertise and support, ensuring rapid deployment and operational continuity.

Furthermore, investments in ZEISS industrial life science workflow solutions are aligned with the 3D High-Content Analysis (HCA) roadmap, paving the way for automation and a transition into High-Throughput Screening (HTS) workflows in future.

The prospect of such an alliance reflects a shared commitment to innovation, customer-centric solutions, and advancing the biopharma industry. By working together, ZEISS and EDGE Biotechnologies aspire to set a new standard for industrial-scale bioimaging as a strategic enabler in biopharma.